Nadeem Ahmad Afzal
Associate Professor (Hon)
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Background and aims Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking. We assessed the therapeutic response to help close this gap. Methods This retrospective study involved 30 sites worldwide. Demographic, clinical, and laboratory data were collected from patients with VEO-IBD who commenced adalimumab therapy before the age of 6 years. Results Seventy-eight patients (37 Crohn’s disease, 26 ulcerative colitis, and 15 with IBD-unclassified) were included. Median age of IBD onset was 2.6 (1.3–4.1) years, with 30 (38.5%) patients diagnosed at age <2 years. Median age at adalimumab initiation was 4.2 (2.8-5.1) years. Adalimumab was used as second-line biologic therapy in 45 (57.7%) patients after infliximab. The median time to last follow-up was 63 (22-124) weeks. Significant improvement in clinical scores, CRP, fecal calprotectin, and weight Z-score were observed by Week 52. Adalimumab durability rates were 61.9%, 48.1%, and 35.6% after 1, 2, and 3 years, respectively. Drug discontinuation rates were not dependent on IBD type, age, prior anti-TNF exposure, or concomitant immunomodulatory treatment. Four (5.1%) patients developed serious infections, including 1 patient with TTC7A deficiency who died following adenovirus sepsis. Conclusion Adalimumab therapy is a viable therapeutic option in patients with VEO-IBD with an acceptable safety profile.
Year:
2025
Purpose : With a rising incidence of childhood-onset Crohn’s disease (CD), linked to genetics, environmental, and lifestyle factors, there is a need to further understand the physical (in)activity behaviors of young people with the condition. We explored the barriers and facilitators to physical activity and exercise in children and young people with CD from the perspectives of patients, caregivers, and specialist clinicians. Methods : Five children, 7 caregivers, and 6 specialist clinicians completed semistructured interviews in this UK-based qualitative study. Recordings were transcribed verbatim, and emergent themes were inductively derived. Results : Three overarching themes were constructed: (1) navigating barriers to a physically active lifestyle with CD, (2) building knowledge and support for a physically active lifestyle with CD, and (3) creating an enabling environment for a physically active lifestyle through family and social support networks. Conclusion : Young people living with CD, their caregivers, and clinicians clearly value the importance of physical activity and exercise but face several disease-specific barriers that can hinder long-term participation. Targeted educational and practical support is needed to address these challenges. Involving those with lived experience is essential in designing effective resources and home-based support programs that meet their needs.
Year:
2025
Objective Pediatric inflammatory bowel diseases (PIBDs), despite being more prevalent in westernized nations, show an increasing incidence worldwide. Accurate evaluation, diagnosis, therapy, and monitoring are mandatory for the adequate management of patients, as is a sensible use of expensive resources, which may be limited in some parts of the world. This limitation often poses challenges to diagnose and treat patients. As the long‐term prognosis very much depends on early diagnosis and remission of active disease, it is important to consider reasonable alternatives that may help clinicians to act accordingly within resource constraints, without downgrading previously published guidelines. Methods A group of experts from the “Paediatric IBD Porto Group” of European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) as well as pediatric and adult IBD experts, trained in IBD centers and having working experience in limited‐resource settings (LR settings), joined efforts to suggest alternative options in settings where resources are limited, while prioritizing an acceptable cost‐effectiveness ratio. Almost all recently published ESPGHAN guidelines and position papers on PIBD were evaluated, and the writing group framed proposals for adaptation in situations with limited access to more expensive resources or tools. Results Ninety consensus‐based recommendations, derived from the available evidence, were formulated. Diagnostic protocol, biochemical evaluation, imaging and endoscopy, monitoring and options for nutritional, medical and surgical treatment were addressed. Cooperation between professionals and institutions was suggested to improve quality of care and optimize use of available expertise. Patient education, counseling, mental health and transition of care were also addressed. Conclusion Diagnosis and management of PIBD are complex and costly in medical resources, but some alternative protocols could provide acceptable results and help with accurate diagnosis and management. These recommendations and practice points may offer useful guidance in settings where resources may be limited while still providing good medical practice.
Year:
2025
Background Thiopurine drugs are effective treatment options in inflammatory bowel disease and other conditions but discontinued in some patients due to toxicity. Methods We investigated thiopurine-induced toxicity in a pediatric inflammatory bowel disease cohort by utilizing exome sequencing data across a panel of 46 genes, including TPMT and NUDT15. Results The cohort included 487 patients with a median age of 13.1 years. Of the 396 patients exposed to thiopurines, myelosuppression was observed in 11%, gastroenterological intolerance in 11%, hepatotoxicity in 4.5%, pancreatitis in 1.8%, and “other” adverse effects in 2.8%. TPMT (thiopurine S-methyltransferase) enzyme activity was normal in 87.4%, intermediate 12.3%, and deficient in 0.2%; 26% of patients with intermediate activity developed toxicity to thiopurines. Routinely genotyped TPMT alleles associated with defective enzyme activity were identified in 28 (7%) patients: TPMT*3A in 4.5%, *3B in 1%, and *3C in 1.5%. Of these, only 6 (21%) patients developed toxic responses. Three rare TPMT alleles (*3D, *39, and *40) not assessed on routine genotyping were identified in 3 patients, who all developed toxic responses. The missense variant p.R139C (NUDT15*3 allele) was identified in 4 patients (azathioprine 1.6 mg/kg/d), but only 1 developed toxicity. One patient with an in-frame deletion variant p.G13del in NUDT15 developed myelosuppression at low doses. Per-gene deleteriousness score GenePy identified a significant association for toxicity in the AOX1 and DHFR genes. Conclusions A significant association for toxicity was observed in the AOX1 and DHFR genes in individuals negative for the TPMT and NUDT15 variants. Patients harboring the NUDT15*3 allele, which is associated with myelosuppression, did not show an increased risk of toxicity.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (14)
Holm Uhlig
Director Centre for Human Genetics
University of Oxford
James Ashton
University of Southampton
Heather Hunter
Lecturer in Sport and Exercise Psychology
University of Gloucestershire
James Faulkner
Associate Professor
University of Southampton
Michel Erlewyn-Lajeunesse
University of Southampton
Johanna Escher
Full professor
Erasmus University Rotterdam
J. R. Fraser Cummings
University Hospital Southampton NHS Foundation Trust
Thierry R F Middleton
Assistant Professor
University of Portsmouth
Zoe Saynor
Research Lead for the Physiology of Health, Lifestyle & Exercise (PHLEX) team
University of Portsmouth
Lauren Collen
Boston Children's Hospital
Patrick van Rheenen
Pediatric Gastroenterologist, Head IBD Unit
University Medical Center Groningen
Elizabeth Spencer
Associate Professor of Pediatric Gastroenterology & Nutrition
Mount Sinai Hospital
Sarah Ennis
Professor of Genomics
University of Southampton
Danielle Lambrick
University of Southampton
Make your next move.
Prepare your application
Review drafts before you send them.